Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 2017 of 6351
-
Estrogen plus talk therapy shows promise for PTSD in women
Symptom relief CompletedThe purpose of this research study is to determine if taking a pill of estradiol (E2) together with prolonged exposure (PE) therapy can improve this treatment outcome in women diagnosed with Post-Traumatic Stress Disorder (PTSD). 80 subjects will take part in this research study …
Phase 3 • Sponsor: The University of Texas Health Science Center, Houston • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Fiber fix: diet study hopes to boost cancer immunotherapy
Knowledge-focused OngoingThis is a randomized, double-blind, fully controlled feeding study that will enroll melanoma patients starting standard-of-care ICB in three settings: adjuvant, neoadjuvant, and unresectable. Patients are randomized to the high fiber or healthy control diet. The goal of the study…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
New bypass device could spare rectal cancer patients from stoma surgery
Disease control Recruiting nowA randomized trial to assess the safety and efficacy of CG-100 for reducing stoma creation rate in subjects undergoing mesorectal excision.
Sponsor: Colospan Ltd. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Electric field device takes on liver tumors in early trial
Disease control Stopped earlyThis phase I trial studies the side effects and best dose of combination chemotherapy and bevacizumab, and to see how well they work with the NovoTTF-100L(P) system in treating participants with cancer that has come back or does not respond to treatment and has spread to the live…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Asthma drug dupilumab targets lung mucus in new imaging study
Disease control CompletedPrimary Objective: • To assess the effect of dupilumab on lung inflammation and related changes in airway volumes detectable by functional respiratory imaging Secondary Objective: * To evaluate the effect of dupilumab at Week 24 on bronchodynamics, hyperinflation, airway resis…
Phase 4 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 26, 2026 15:05 UTC
-
Music and language may reveal hidden consciousness in brain injury patients
Knowledge-focused Recruiting nowThe purpose of this research study to find out if clinically unconscious acute brain injury patients that show brain activation to music and language on electroencephalogram (EEG) (bedside test) have better outcomes and wake up in the future.
Sponsor: University of Miami • Aim: Knowledge-focused
Last updated Sep 09, 2026 23:00 UTC
-
New program helps kids with type 1 diabetes take control
Disease control CompletedThe 4T program encompasses: Teamwork, Targets, Technology, and Tight Range. These methods will help patients better manage their condition of Type 1 Diabetes with improved patient-reported outcomes.
Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for drug-resistant lung cancer: combo therapy tested in early trial
Disease control CompletedThis phase Ib trial studies the best dose, safety, and effect of alisertib or sapanisertib, in combination with osimertinib, in treating patients with EGFR mutated stage IIIB or IV non-small cell lung cancer that does not respond to osimertinib treatment (osimertinib resistant). …
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
One vaccine to fight five types of meningitis? pfizer tests new combo shot in teens
Vaccine CompletedThis study is designed to describe the short-term immunogenicity and safety of 2 doses of Neisseria meningitidis group A, B, C, W, and Y vaccine (MenABCWY) separated by either 12 or 36 months during adolescence, and immunopersistence up to 24 months after completing 2 doses separ…
Phase 2 • Sponsor: Pfizer • Aim: Vaccine
Last updated Jun 27, 2026 12:25 UTC
-
New drug combo aims to outsmart resistant breast cancer
Disease control OngoingThis phase I trial studies the effects (good and bad) of adding copanlisib to the usual therapy of fulvestrant and abemaciclib in treating patients with hormone receptor positive and HER2 negative breast cancer that has spread from where it first started (breast) to other places …
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 09, 2026 23:00 UTC
-
VR therapy eases sensory struggles in autism
Symptom relief Recruiting nowThis study aims to establish a cognitive-behavior therapy (CBT) based virtual exposure (VR) exposure program to train ASD adults coping with everyday sensory scenarios. Through the practice and training, the ASD participants may learn the strategy to deal with the common sensory …
Sponsor: National Taiwan University Hospital • Aim: Symptom relief
Last updated Aug 02, 2026 00:00 UTC
-
Proton vs X-Ray: which radiation causes fewer side effects in breast cancer?
Disease control OngoingThis phase III trial compares the rate of complications of x-ray therapy versus proton beam radiation therapy after breast conserving surgery or mastectomy in treating patients with breast cancer. X-ray therapy is a form of radiation therapy that uses high-energy radiation from x…
Phase 3 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug cocktail shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis phase I/Ib trial studies the side effects and best dose of parsaclisib with or without polatuzumab-vedotin (Pola) plus the standard drug therapy (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone \[PaR-CHOP\]) and to see how well the…
Phase 1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Can a computer program help inmates care for aging prisoners?
Knowledge-focused CompletedThe demographics of the U.S. prison population are shifting at a dramatic rate requiring new approaches to prison healthcare. Current estimates suggest that there are 2.3 million incarcerated persons in the U.S. Similar to the free world, the aging of the Baby Boom generation is …
Sponsor: Klein Buendel, Inc. • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
New Once-Nightly pill could simplify narcolepsy treatment
Symptom relief CompletedAn Open Label Study to Evaluate Long-Term Safety and Tolerability of a Once Nightly Formulation of Sodium Oxybate for Extended-Release Oral Suspension (FT218) and the ability to switch from twice-nightly immediate release sodium oxybate to once-nightly FT218 for the Treatment of …
Phase 3 • Sponsor: Avadel • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC
-
Poop pills show promise for gut disease
Disease control CompletedThe goal of this placebo-controlled randomised multicenter trial is to evaluate the efficacy and safety of anaerobic prepared donor fecal microbiota transplantation (FMT) compared to autologous FMT in patient with ulcerative colitis. Participants will receive 4 treatments with f…
Phase 2 • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New combo aims to stop liver cancer recurrence in High-Risk patients
Disease control CompletedHepatocellular carcinoma (HCC) is one of the most common malignant tumors, with more than 700,000 new cases in the world every year. China has the highest incidence and death rate of HCC in the world, accounting for 55% of the world's annual incidence and 45% of the world's annua…
Phase 1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New hope for tough childhood cancer: experimental drug targets aurora kinase
Disease control OngoingThe reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Experimental drug ARRY-614 paired with immunotherapy shows promise in early cancer trial
Disease control OngoingIn this study, the Phase Ib portion aims to establish safety and tolerability of ARRY-614 with either nivolumab or ipilimumab and to determine a recommended phase II dose of ARRY-614 in combination with either nivolumab or nivolumab+ipilimumab immunotherapy in patients with selec…
Phase 1/2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Donor cells take on tough leukemia in early trial
Disease control CompletedThis phase I trial studies the side effects of donor natural killer (NK) cell therapy in treating patients with acute myeloid leukemia that has come back (recurrent) or has not responded to treatment (refractory). Natural killer cells are a type of immune cell. Immunotherapy with…
Phase 1 • Sponsor: Sumithira Vasu • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC